EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond Catalysis: Physiology, Cellular Biology And Therapeutic Strategies for Metallo-β-Lactamase-Producing Pathogens

Brenda A Warecki iD, Clarisa Parodi, Fernanda D Romero iD, Lisandro J González, Alejandro J Vila iD

ACS Infectious Diseases · 13.11.2026 · 12 (11) · 3612-3629

DOI: 10.1021/acsinfecdis.6c00699 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Infectious Diseases, online erschienen am 08.10.2026. Verfasst von Brenda A Warecki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biología Molecular y Celular de Rosario (IBR), CONICET, Universidad Nacional de Rosario, Ocampo y Esmeralda, Rosario2000, Argentina. Hauptthemen laut MEDLINE: beta-Lactamases, Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit nennt 184 Literaturangaben. Gefördert von: Ministerio de Ciencia, Tecnolog?a e Innovaci?n, Agencia Santafesina de Ciencia, Tecnolog?a e Innovaci?n, Agencia Nacional de Promoci?n de la Investigaci?n, el Desarrollo Tecnol?gico y la Innovaci?n.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metallo-β-lactamases (MBLs) are zinc-dependent β-lactamases that threaten the clinical utility of carbapenems and other last-line β-lactams in Gram-negative pathogens. Their impact cannot be explained solely based on their catalytic efficiency. Clinically relevant MBLs differ in substrate profiles, cellular localization, metal dependence, periplasmic stability, and host compatibility. These features shape both resistance phenotypes and the dissemination of MBL genes after horizontal transfer. Recent therapeutic progress has exploited vulnerabilities in this landscape. Cefiderocol circumvents permeability barriers through siderophore-mediated uptake but can be compromised by expression of New Delhi MBL and iron-transport defects. Aztreonam, uniquely stable to most B1 MBLs, has been revived through protection by avibactam against coproduced serine β-lactamases. Zidebactam-containing combinations exploit β-lactam enhancement targeting penicillin-binding protein 2 rather than direct MBL inhibition. Meanwhile, broad-spectrum boronates such as taniborbactam and xeruborbactam illustrate both the promise and the evolutionary fragility of direct inhibitor strategies. Beyond therapeutics, emerging work on MBL biogenesis, zinc limitation, periplasmic protein quality control, and host-specific expression reveals that resistance is a physiological phenotype, not simply an enzymatic trait. This review integrates biochemical, cellular, evolutionary, and clinical perspectives to highlight why MBL-mediated resistance requires context-aware diagnostics, surveillance, and precision therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesAnti-Bacterial AgentsGram-Negative BacteriaHumansCefiderocolbeta-Lactamsbeta Lactam Antibioticsbeta-Lactamase InhibitorsGram-Negative Bacterial InfectionsCarbapenems

Stichwörter der Autor:innen

aztreonam-avibactamboronatescarbapenem resistancecefiderocoldiazabicyclooctaneshost-dependent resistancemetallo-β-lactamasesnutritional immunityperiplasmic proteostasisprotein quality controlzinc starvation

Substanzen

beta-LactamasesAnti-Bacterial AgentsCefiderocolbeta-Lactamsbeta Lactam Antibioticsbeta-Lactamase InhibitorsCarbapenems

Autor:innen und Institutionen

  • Instituto de Biología Molecular y Celular de Rosario (IBR), CONICET, Universidad Nacional de Rosario, Ocampo y Esmeralda, Rosario2000, Argentina.
  • Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, Rosario2000, Argentina.

ORCID-Profile: Brenda A Warecki, Fernanda D Romero, Alejandro J Vila

Förderung

  • Ministerio de Ciencia, Tecnolog?a e Innovaci?n
  • Agencia Santafesina de Ciencia, Tecnolog?a e Innovaci?n
  • Agencia Nacional de Promoci?n de la Investigaci?n, el Desarrollo Tecnol?gico y la Innovaci?n

Zitieren

APA

Warecki, B. A., Parodi, C., Romero, F. D., González, L. J., & Vila, A. J. (2026). Beyond Catalysis: Physiology, Cellular Biology And Therapeutic Strategies for Metallo-β-Lactamase-Producing Pathogens. ACS Infectious Diseases, 12(11), 3612-3629. https://doi.org/10.1021/acsinfecdis.6c00699

Vancouver

Warecki BA, Parodi C, Romero FD, González LJ, Vila AJ. Beyond Catalysis: Physiology, Cellular Biology And Therapeutic Strategies for Metallo-β-Lactamase-Producing Pathogens. ACS Infectious Diseases. 2026;12(11):3612-3629. doi:10.1021/acsinfecdis.6c00699

BibTeX
@article{Warecki2026,
  author = {Warecki, Brenda A and Parodi, Clarisa and Romero, Fernanda D and González, Lisandro J and Vila, Alejandro J},
  title = {Beyond Catalysis: Physiology, Cellular Biology And Therapeutic Strategies for Metallo-β-Lactamase-Producing Pathogens},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {11},
  pages = {3612--3629},
  doi = {10.1021/acsinfecdis.6c00699}
}
Kostenlos starten →